Upper limb lymphedema 27 (ULL27): Dutch translation and validation of an illness-specific health-related quality of life questionnaire for patients with upper limb lymphedema
Platelets rush to the fracture site within minutes, forming a hematoma that serves as a biological scaffold
TB-500 administration: Subcutaneous injection
because rigorously controlled human safety data specific to the TB-500 fragment does not exist, its longer-term risk profile, including possible immune reactions, remains unknown Evidence snapshot: Evidence for TB-500 itself is preclinical, drawn mainly from cell-culture and animal studies (a 1999 rat wound-healing study and later rodent cardiac- and tendon-injury models), with a 2026 scoping review describing the musculoskeletal literature on thymosin beta-4 and TB-500 as sparse and largely preclinical
Should additional safety concerns be identified, Health Canada will take appropriate action to protect public health and safety, including communicating updates, if needed
And what exactly is the other 2 per cent
